These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10607253)

  • 1. Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy.
    Colloredo G; Roffi L; Brunetto MR; Leandro G; Brugnetti B; Bissoli F; Scalori A; Mancia G; Civardi E; Idéo G; Bonino F; Bellati G
    J Viral Hepat; 1999 Sep; 6(5):373-80. PubMed ID: 10607253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
    Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
    Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of hepatitis C virus RNA predict non-response to interferon therapy: comparison of two commercial assays.
    Soffredini R; Rumi MG; Del Ninno E; Parravicini ML; Russo A; Colombo M
    J Viral Hepat; 1999 Jan; 6(1):65-71. PubMed ID: 10847132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C.
    Castro FJ; Esteban JI; Juárez A; Sauleda S; Viladomiu L; Martell M; Moreno F; Allende H; Esteban R; Guardia J
    J Viral Hepat; 2002 May; 9(3):202-7. PubMed ID: 12010508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
    Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessment of hepatitis C virus RNA in peripheral blood mononuclear cells during therapy with interferon-alpha2a.
    Moonka DK; Henzel BS; Gutekunst K; O'Brien CB
    J Viral Hepat; 1998 Jan; 5(1):27-33. PubMed ID: 9493514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
    Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
    Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C.
    Saito H; Ebinuma H; Satoh I; Miyaguchi S; Tada S; Iwabuchi N; Kumagai N; Tsuchimoto K; Morizane T; Ishii H
    J Viral Hepat; 2000 Jan; 7(1):64-74. PubMed ID: 10718945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.
    Knolle PA; Kremp S; Höhler T; Krummenauer F; Schirmacher P; Gerken G
    J Viral Hepat; 1998 Nov; 5(6):399-406. PubMed ID: 9857349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group.
    Chemello L; Cavalletto L; Bernardinello E; Boccato S; Casarin P; Cavinato F; Urban F; Pontisso P; Cecchetto A; Gatta A; Alberti A
    J Viral Hepat; 1999 Jul; 6(4):321-7. PubMed ID: 10607247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative viremia test for early prediction of a biochemical response in patients with chronic hepatitis C treated with interferon.
    Nardiello S; Gaeta GB; Pizzella T; Stornaiuolo G; Ascione T; Galanti B; Giusti G
    J Chemother; 2001 Aug; 13(4):424-8. PubMed ID: 11589486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C.
    Kakizaki S; Takagi H; Yamada T; Ichikawa T; Abe T; Sohara N; Kosone T; Kaneko M; Takezawa J; Takayama H; Nagamine T; Mori M
    J Viral Hepat; 1999 Jul; 6(4):315-9. PubMed ID: 10607246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a.
    Sarrazin C; Hendricks DA; Sedarati F; Zeuzem S
    J Clin Microbiol; 2001 Aug; 39(8):2850-5. PubMed ID: 11474002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
    Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
    J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
    Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
    J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells.
    Kusaka S; Okusa T; Araki A; Fujiki K; Takashimizu I; Okayasu I; Yamamoto N; Sato C
    J Med Virol; 1995 Jul; 46(3):265-8. PubMed ID: 7561801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b.
    Tong MJ; Blatt LM; Tong LT; Sayadzadeh K; Conrad A
    J Viral Hepat; 1998 Sep; 5(5):323-31. PubMed ID: 9795916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.